Literature DB >> 26462919

Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.

Phillip J Koo1, Jennifer J Kwak2, Sajal Pokharel3, Peter L Choyke4.   

Abstract

Imaging of prostate cancer presents many challenges to the imaging community. There has been much progress in this space in large part due to MRI and PET radiopharmaceuticals. Though MRI has been focused on the evaluation of local disease and PET on the detection of metastatic disease, these two areas do converge and will be complementary especially with the growth of new PET/MRI technologies. In this review article, we review novel MRI, MRI/US, and PET radiopharmaceuticals which will offer insight into the future direction of imaging in prostate cancer.

Entities:  

Keywords:  Acetate; Bombesin; DKI; DWI; FACBC; FDHT; Fusion; GRP; Hyperpolarized; MRI; MRI/US; PET; PET/CT; PSMA; Prostate cancer

Mesh：

Substances：

Year:  2015        PMID： 26462919      PMCID： PMC6364699          DOI： 10.1007/s11912-015-0480-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  77 in total

1.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 3.  Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer.

Authors:  Y Liu
Journal:  Prostate Cancer Prostatic Dis       Date:  2006-05-09       Impact factor: 5.554

Review 4.  Challenges and recommendations for early identification of metastatic disease in prostate cancer.

Authors:  E David Crawford; Nelson N Stone; Evan Y Yu; Phillip J Koo; Stephen J Freedland; Susan F Slovin; Leonard G Gomella; E Roy Berger; Thomas E Keane; Paul Sieber; Neal D Shore; Daniel P Petrylak
Journal:  Urology       Date:  2014-01-08       Impact factor: 2.649

5.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.

Authors:  Peter A Pinto; Paul H Chung; Ardeshir R Rastinehad; Angelo A Baccala; Jochen Kruecker; Compton J Benjamin; Sheng Xu; Pingkun Yan; Samuel Kadoury; Celene Chua; Julia K Locklin; Baris Turkbey; Joanna H Shih; Stacey P Gates; Carey Buckner; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Peter L Choyke; Bradford J Wood
Journal:  J Urol       Date:  2011-08-17       Impact factor: 7.450

6.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

Authors:  Martina Benešová; Martin Schäfer; Ulrike Bauder-Wüst; Ali Afshar-Oromieh; Clemens Kratochwil; Walter Mier; Uwe Haberkorn; Klaus Kopka; Matthias Eder
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

7.  Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer.

Authors:  Bert-Ram Sah; Irene A Burger; Roger Schibli; Matthias Friebe; Ludger Dinkelborg; Keith Graham; Sandra Borkowski; Claudia Bacher-Stier; Ray Valencia; Ananth Srinivasan; Thomas F Hany; Linjing Mu; Peter J Wild; Niklaus G Schaefer
Journal:  J Nucl Med       Date:  2015-02-12       Impact factor: 10.057

Review 8.  Novel tracers and their development for the imaging of metastatic prostate cancer.

Authors:  Andrea B Apolo; Neeta Pandit-Taskar; Michael J Morris
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

9.  Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.

Authors:  Baris Turkbey; Esther Mena; Joanna Shih; Peter A Pinto; Maria J Merino; Maria L Lindenberg; Marcelino Bernardo; Yolanda L McKinney; Stephen Adler; Rikard Owenius; Peter L Choyke; Karen A Kurdziel
Journal:  Radiology       Date:  2013-11-08       Impact factor: 11.105

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315
View more
  4 in total

1.  Prostate cancer: The applicability of textural analysis of MRI for grading.

Authors:  Frederick Kelcz; David F Jarrard
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

Review 2.  PET imaging of recurrent and metastatic prostate cancer with novel tracers.

Authors:  Francesca V Mertan; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Future Oncol       Date:  2016-08-16       Impact factor: 3.404

Review 3.  Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.

Authors:  David G Calatayud; Sotia Neophytou; Eleni Nicodemou; S Giuseppe Giuffrida; Haobo Ge; Sofia I Pascu
Journal:  Front Chem       Date:  2022-04-12       Impact factor: 5.545

Review 4.  Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.

Authors:  Sandra Bednarova; Maria L Lindenberg; Maria Vinsensia; Chiara Zuiani; Peter L Choyke; Baris Turkbey
Journal:  Transl Androl Urol       Date:  2017-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.